Article

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cells

2023-01-09

Abstract excerpt

Pancreatic cancer (PC) is one of top deadliest cancer types, p53 was found mutated in about 75% of PC patients. Hence, mutant/wild-type p53 protein may represent a unique therapeutic target. Interestingly, a p53-reactivator (PRIMA-1 MET ) was recently approved by FDA and showed promise in hematological malignancies, therefore, warrants an in vitro evaluation in PC cell lines. The aim of this study was valuation o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a4847e57-4c7f-5c16-8d45-99c4283e568f
DOI: 10.22541/au.167303805.53660561/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsDOI 10.22541/au.167303805.53660561/v2Read

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Semantic proximity Read

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.Semantic proximity Read

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Semantic proximity Read

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsSemantic proximity Read

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma.Semantic proximity Read

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read

Calcitriol enhances gemcitabine antitumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model systemSemantic proximity Read

Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of LiteraturesSemantic proximity Read